Ποια είναι η τιμή για Curatis Holding AG (CURN)

Η τιμή για Curatis Holding AG (CURN) είναι $25.36

Ποια είναι η κεφαλαιοποίηση αγοράς για Curatis Holding AG (CURN)

Η κεφαλαιοποίηση αγοράς για Curatis Holding AG (CURN) είναι $134.44M

Curatis Holding AG (CURN) Τιμή και Κεφαλαιοποίηση Αγοράς

Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.

Η τιμή για CURN	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$983,059 $134.44M	NVDA	$5.211T	+3,876,177.17%
$857,686 $134.44M	AAPL	$4.547T	+3,381,822.88%
$785,199 $134.44M	GOOG	$4.162T	+3,095,998.34%
$677,735 $134.44M	MSFT	$3.593T	+2,672,259.79%
$526,837 $134.44M	AMZN	$2.793T	+2,077,257.73%

Η τιμή για CURN

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$983,059 $134.44M